Liver and viral disease specialist Aligos Therapeutics (NASDAQ: ALGS) announced last week a significant partnership with biopharmaceutical company Xiamen Amoytop Biotech (SHA: 688278) for the research and development (R&D) of live disease-targeting oligonucleotide compounds. These compounds are discovered using Aligos’s proprietary platform, marking a step forward in the treatment of liver diseases.
Financial Terms and Global Reach of the Partnership
Under the terms of the agreement, Aligos is set to receive an upfront payment and research funding, along with the potential for up to USD 109 million in milestone payments and sales royalties. This partnership not only provides financial benefits to Aligos but also grants commercialization rights for Greater China to Amoytop Biotech and Aligos for the rest of the world, respectively. This global distribution of rights underscores the broad potential impact of the R&D collaboration.
The Potential Impact on Liver Disease Treatments
The collaboration between Aligos Therapeutics and Xiamen Amoytop Biotech aims to leverage Aligos’s platform to develop innovative oligonucleotide compounds that target live diseases. This strategic partnership has the potential to accelerate the discovery and development of new treatments, ultimately benefiting patients worldwide.-Fineline Info & Tech
